PROCEPT BioRobotics Corp
PRCT Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$19.83
KIRA · Stoqly’s AI analyst, in plain words
- PROCEPT BioRobotics Corp had $308M of revenue in fiscal 2025, up 37.2% on the year before. Over five years, revenue changed +109.0% a year on average.
- Its operating margin was −33.7%, up 9.3 pts: of every 100 in sales, about −34 is left after running the business.
- PROCEPT BioRobotics Corp lost $95.6M in fiscal 2025.
- Free cash flow was −$58.3M in fiscal 2025, −18.9% of revenue.
- PROCEPT BioRobotics Corp has $235M more cash than debt.
Market cap
$1.1B
P/E
—
Revenue
$308M
Net income
−$95.6M
Free cash flow
−$58.3M
Operating margin
−33.7%
PROCEPT BioRobotics Corp in 30 seconds · fiscal 2025
Are sales growing?
+37.2%
Yes. Sales grew 37.2% last year.
Does it make a profit?
−31.0%
No. It lost money last year.
Does profit turn into cash?
−18.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What PROCEPT BioRobotics Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- PROCEPT BioRobotics Corp
- CIK
- 0001588978
PROCEPT BioRobotics Corp · PRCT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $34.5M | $75.0M | $136M | $224M | $308M |
| Revenue growth | 346.7% | 117.6% | 81.6% | 64.8% | 37.2% |
| Gross margin | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Operating margin | −157.1% | −107.6% | −80.2% | −43.0% | −33.7% |
| Net income | −$59.9M | −$87.2M | −$106M | −$91.4M | −$95.6M |
| Net margin | −173.6% | −116.2% | −77.8% | −40.7% | −31.0% |
| Diluted EPS | −$3.63 | −$1.96 | −$2.24 | −$1.75 | −$1.72 |
| Cash | |||||
| Cash from operations | −$57.3M | −$80.4M | −$108M | −$99.2M | −$49.0M |
| Capital expenditure | $0.6M | $2.7M | $25.2M | $4.4M | $9.4M |
| Free cash flow | −$57.9M | −$83.0M | −$133M | −$104M | −$58.3M |
| FCF margin | −168.0% | −110.7% | −97.8% | −46.2% | −18.9% |
| Share count change | 349.9% | 169.4% | 6.4% | 10.3% | 6.6% |
| Debt and strength | |||||
| Cash and short-term investments | $304M | $222M | $257M | $334M | $287M |
| Debt incl. finance leases | $50.0M | $51.2M | $51.3M | $51.5M | $51.6M |
| Shareholders' equity | $267M | $197M | $281M | $402M | $366M |
| Current ratio | 20.1x | 7.7x | 7.6x | 9.1x | 6.8x |
| Interest coverage | −9.3x | −15.6x | −27.3x | −23.1x | −29.0x |
| Returns and quality | |||||
| Return on capital | −334.9% | −241.3% | −115.2% | −63.6% | −62.6% |
| Return on equity | −142.2% | −37.6% | −44.3% | −26.8% | −24.9% |
| Return on tangible equity | −22.4% | −44.2% | −37.7% | −22.7% | −26.1% |
| Piotroski F-score | 6 | 3 | 4 | 5 | 3 |
| Altman Z'' | 6.4 | 1.4 | 1.8 | 3.9 | 2.2 |
Insiders bought, 12 months
$11.0M
2 insiders
Insiders sold, 12 months
$0.6M
3 insiders
Of sales under plans
36%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
PROCEPT BioRobotics Corp · PRCT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $19.83 a share, the company is worth $1.1B.
Source: SEC EDGAR XBRL filings (CIK 0001588978). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.